Status:
COMPLETED
Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion.
Lead Sponsor:
Kidney Cancer Research Bureau
Conditions:
Renal Cell Cancer Metastatic
Non-small Cell Lung Cancer Metastatic
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Patients with advanced cancers who have pleural effusion, especially those requiring pleural evacuation, experienced poorer survival when treated with immunotherapy. The pleura also acts as a natural ...
Detailed Description
Patients ≥18 years old who have large volume of pleural effusion, required evacuation, and received systemic therapy with a checkpoint inhibitor (monotherapy or combination with another checkpoint inh...
Eligibility Criteria
Inclusion
- Patients ≥18 years old
- Large volume of pleural effusion (1 liter and more), required evacuation
- Systemic therapy with a checkpoint inhibitor (monotherapy or combination with another checkpoint inhibitor)
- Metastatic cancers (renal cell carcinoma (RCC) and non-small cell lung cancer (NSCLC)
Exclusion
- Autoimmune disorders
- Previous treatment for
Key Trial Info
Start Date :
August 10 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2023
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT04749602
Start Date
August 10 2020
End Date
March 1 2023
Last Update
March 8 2023
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
I.M. Sechenov First Moscow State Medical University
Moscow, Russia
2
Kidney Cancer Research Bureau
Moscow, Russia
3
Medicine 24/7 clinic
Moscow, Russia
4
Medscan
Moscow, Russia